Neuromodulation: Spinal Cord Stimulation Devices Market
Neuromodulation: Spinal Cord Stimulation Devices Market
$4,750.00
Despite the severe impact of the COVID-19 pandemic on elective surgeries, global sales of neuromodulation systems for the treatment of chronic, intractable pain—which include innovative implantable spinal cord stimulation (SCS) devices and associated products—is expected to increase at a healthy CAGR of approximately 8.6%, from nearly $3bn in 2019 to an estimated $4.5bn in 2024.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Executive Summary
This report provides an overview of chronic pain and treatment with implantable neuromodulation systems called spinal cord stimulation (SCS) devices. Implantable SCS devices have been utilized with a high degree of success for decades, particularly in the US but also in Europe and increasingly in other regions, where they have become a life-changing therapy option for thousands of suffering patients.
Overview
Despite the severe impact of the COVID-19 pandemic on elective surgeries, global sales of neuromodulation systems for the treatment of chronic, intractable pain—which include innovative implantable spinal cord stimulation (SCS) devices and associated products—is expected to increase at a healthy CAGR of approximately 8.6%, from nearly $3bn in 2019 to an estimated $4.5bn in 2024.
A healthy rebound is expected to occur in SCS beginning in 2021 based on an expected successful vaccine and/or treatments, and a resurgence of procedures deferred in 2020 due to pent-up demand from an aging population suffering from chronic, debilitating pain in need of safer and more effective therapy alternatives to potentially dangerous and addictive opioids. There is strong demand for SCS from a growing number of intractable pain patients who have failed back/spine surgery, are not eligible for/cannot afford spine surgery, and have failed conventional treatment options.
SCS is the largest neuromodulation device market, and SCS technology is supported by a long clinical history, demonstrating a substantial reduction in excruciating pain (50% or higher reduction) in most patients. Next-generation systems aim to improve pain relief even further by offering more precise targeting, superior pain coverage, multiple and customized waveforms, proprietary algorithms/software and apps, and other innovations.
Key competitors in the SCS market include: Medtronic, Boston Scientific, Abbott, and Nevro. While major medical device companies dominate this highly competitive market, a handful of startups have attempted to enter the space, and successful companies (eg Saluda Medical) are partnering with key players to advance proprietary advanced technologies.
This comprehensive medical market and technology report provides:
- overview of chronic pain
- SCS technologies, key product, and features
- emerging technologies/pipelines and innovations
- in-depth market and competitive analyses, including market drivers/limiters, 5-year market forecasts by segment and region, and global/regional market share
- overview of companies, financials, and strategic growth plans
Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. Market forecasts are for the 2019-24 time period.
View this related report : https://pharmastore.informa.com/product/neuromodulation-deep-brain-stimulation-and-vagus-nerve-stimulation-devices-market/
Table of Contents
Executive Summary……………………………………………………………………………………………….. ES-1
i. SCS devices market ………………………………………………………………………………………………ES-1
a. SCS sales by region…………………………………………………………………………………..ES-4
b. Market leaders………………………………………………………………………………………..ES-6
ii. Methodology………………………………………………………………………………………………………ES-8
Exhibit ES-1: Spinal cord stimulation devices, global market forecast ($m), 2019–24 ……… ES-3
Exhibit ES-2: Spinal cord stimulation devices market, estimated sales and share of revenues by region, 2019 …………………………………………………………………… ES-4
Exhibit ES-3: Spinal cord stimulation devices market, forecast sales by region ($m), 2019–24 ………………………………………………………………………………………….. ES-5
Exhibit ES-4: Spinal cord stimulation devices market, estimated global share by supplier, 2019……………………………………………………………………………………………….. ES-6
1. Clinical Overview…………………………………………………………………………………………………. 1-1
1.1 Chronic pain ……………………………………………………………………………………………………… 1-1
1.2 Spinal cord, nerves, and the transmission of pain………………………………………………….. 1-2
1.3 The central nervous system versus peripheral nervous system……………………………….. 1-4
1.4 Pain statistics ……………………………………………………………………………………………………. 1-6
1.5 Cost of pain ………………………………………………………………………………………………………. 1-7
1.6 Pain treatment………………………………………………………………………………………………….. 1-7
1.7 Opioid abuse and deaths……………………………………………………………………………………. 1-8
1.8 Procedural therapies for treating pain …………………………………………………………………. 1-9
1.9 Spinal cord stimulation …………………………………………………………………………………….. 1-10
1.10 Bibliography ………………………………………………………………………………………………….. 1-15
Exhibit 1-1: Diagram of the spine and spinal cord……………………………………………………… 1-3
Exhibit 1-2: The nervous system, including the four types of nerves…………………………….. 1-4
Exhibit 1-3: Selected types of chronic pain, estimated US prevalence…………………………… 1-7
Exhibit 1-4: The US opioid epidemic by numbers, 2018 ……………………………………………… 1-9
Exhibit 1-5: Diagram of cardiac pacemaker implantation …………………………………………. 1-11
Exhibit 1-6: Basic diagram of SCS system implantation…………………………………………….. 1-12
2. Neuromodulation Technologies for the Treatment of Pain …………………………………………. 2-1
2.1 Spinal cord stimulation systems ………………………………………………………………………….. 2-1
2.1.1 Abbott……………………………………………………………………………………………….. 2-9
2.1.2 Boston Scientific………………………………………………………………………………… 2-14
2.1.3 Medtronic ………………………………………………………………………………………… 2-21
2.1.4 Nevro ………………………………………………………………………………………………. 2-30
2.1.5 Saluda Medical………………………………………………………………………………….. 2-37
2.1.6 Stimwave………………………………………………………………………………………….. 2-41
2.2 Other minimally invasive pain stimulation systems ……………………………………………… 2-45
2.2.1 Bioness…………………………………………………………………………………………….. 2-46
2.2.2 Mainstay Medical………………………………………………………………………………. 2-51
2.2.3 SPR Therapeutics ………………………………………………………………………………. 2-53
2.3 Bibliography ……………………………………………………………………………………………………. 2-57
Exhibit 2-1: Selected leading spinal cord stimulation systems …………………………………….. 2-4
Exhibit 2-2: Recently FDA-approved spinal cord stimulation systems, 2018–19 ……………… 2-8
Exhibit 2-3: BurstDR stimulation pain relief……………………………………………………………. 2-11
Exhibit 2-4: The new Proclaim XR SCS system…………………………………………………………. 2-12
Exhibit 2-5: St. Jude Medical Invisible Trial System………………………………………………….. 2-15
Exhibit 2-6: Boston Scientific’s original Precision Spectra system, designed with 32 contacts and 32 dedicated power sources…………………………………………. 2-16
Exhibit 2-7: Boston Scientific’s new Spectra WaveWriter SCS system …………………………. 2-18
Exhibit 2-8: Comparison of Spectra WaveWriter’s 32-contact stimulation field versus traditional stimulation ………………………………………………………………………. 2-20
Exhibit 2-9: Medtronic’s new Intellis SCS platform ………………………………………………….. 2-25
Exhibit 2-10: Nevro’s Senza SCS system…………………………………………………………………… 2-31
Exhibit 2-11: Nevro’s new Senza Omnia SCS system………………………………………………….. 2-33
Exhibit 2-12: Saluda Medical’s groundbreaking Evoke SCS ECAP-Controlled Closed-Loop SCS system ………………………………………………………………………………………. 2-38
Exhibit 2-13: Stimwave’s Freedom SCS system…………………………………………………………. 2-44
Exhibit 2-14: Stimulation device startups and nerve targets……………………………………….. 2-46
Exhibit 2-15: Bioness’s StimRouter system for treating peripheral nerve pain……………….. 2-48
Exhibit 2-16: Mainstay Medical’s ReActiv8 system……………………………………………………. 2-52
Exhibit 2-17: SPR Therapeutics’ SPRINT PNS system………………………………………………….. 2-55
3. Market Analysis…………………………………………………………………………………………………… 3-1
3.1 Spinal cord stimulation devices market………………………………………………………………… 3-1
3.1.1 Market forecast: global………………………………………………………………………… 3-1
3.1.2 Market forecast: by region …………………………………………………………………… 3-4
3.1.3 Market drivers and limiters ………………………………………………………………….. 3-6
3.1.4 Market share: global……………………………………………………………………………. 3-8
3.1.5 Market share: by region……………………………………………………………………… 3-12
3.2 Corporate profiles……………………………………………………………………………………………. 3-13
3.2.1 Abbott……………………………………………………………………………………………… 3-13
3.2.2 Boston Scientific………………………………………………………………………………… 3-15
3.2.3 Medtronic ………………………………………………………………………………………… 3-18
3.2.4 Nevro ………………………………………………………………………………………………. 3-26
3.3 Bibliography ……………………………………………………………………………………………………. 3-29
Exhibit 3-1: Spinal cord stimulation devices, global market forecast ($m), 2019–24 ……….. 3-3
Exhibit 3-2: Spinal cord stimulation devices market, estimated sales and share of revenues by region, 2019 …………………………………………………………………….. 3-4
Exhibit 3-3: Spinal cord stimulation devices market, forecast sales by region ($m), 2019–24 ……………………………………………………………………………………………. 3-5
Exhibit 3-4: Spinal cord stimulation devices market, estimated global share by supplier, 2019………………………………………………………………………………… 3-9
Exhibit 3-5: Estimated spinal cord stimulation device revenues, by competitor, 2017–19 ……………………………………………………………………………………………. 3-9
Exhibit 3-6: Spinal cord stimulation devices market ($m), estimated share by supplier and region, 2019 ………………………………………………………………………………. 3-12
Exhibit 3-7: Abbott, revenues by segment, FY2018–19…………………………………………….. 3-14
Exhibit 3-8: Boston Scientific, revenues by segment, FY2018–19 ……………………………….. 3-17
Exhibit 3-9: Medtronic, revenues by segment, FY2019–20………………………………………… 3-25
Appendix A: company listing
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Johnson & Johnson Company Analysis 
Sign up to the